Abstract: 【Abstract】 Research progress in the establishment of long-term control goals and treat-to-target in the treatment of atopic dermatitis （AD） was searched and summarized in this review. The TREatment of ATopic eczema （TREAT） Registry Taskforce defined a minimum follow-up frequency of initially 4 weeks after commencing treatment, then every 3 months while on treatment and every 6 months while off treatment; the international Harmonising Outcome Measures for Eczema （HOME） group recommended that the long-term control of AD should be measured by either the Recap of Atopic Eczema （RECAP） instrument or the Atopic Dermatitis Control Tool （ADCT）. In order to achieve the treat-to-target in AD, a panel comprising 87 participants from 28 countries developed and published “Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies” in early 2021, which recommended 3 months and 6 months as two evaluation time points, and various disease outcome domains spanning symptoms, signs, quality of life plus patient global assessment as the target. By setting the time-specific outcome thresholds, the consensus provided a framework for shared decision-making on systemic treatment adjustment for AD patients. This review summarizes concepts and indicators related to the assessment of long-term control of and treat-to-target in AD, in the hope of providing some ideas for clinical management, especially the long-term control, of AD in China.

Key words: Dermatitis, atopic, Severity of illness index, Long-term control, Assessment evolution, Treat-to-target